NO20091593L - Ketokonazolenantiomer i mennesker - Google Patents

Ketokonazolenantiomer i mennesker

Info

Publication number
NO20091593L
NO20091593L NO20091593A NO20091593A NO20091593L NO 20091593 L NO20091593 L NO 20091593L NO 20091593 A NO20091593 A NO 20091593A NO 20091593 A NO20091593 A NO 20091593A NO 20091593 L NO20091593 L NO 20091593L
Authority
NO
Norway
Prior art keywords
humans
ketoconazole enantiomers
ketoconazole
enantiomers
solvates
Prior art date
Application number
NO20091593A
Other languages
English (en)
Norwegian (no)
Inventor
Timothy Andrew Stewart
Original Assignee
Cortendo Invest Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortendo Invest Ab filed Critical Cortendo Invest Ab
Publication of NO20091593L publication Critical patent/NO20091593L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20091593A 2006-10-02 2009-04-22 Ketokonazolenantiomer i mennesker NO20091593L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84896306P 2006-10-02 2006-10-02
PCT/US2007/080186 WO2008042898A2 (en) 2006-10-02 2007-10-02 Ketoconazole enantiomer in humans

Publications (1)

Publication Number Publication Date
NO20091593L true NO20091593L (no) 2009-04-22

Family

ID=39269161

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091593A NO20091593L (no) 2006-10-02 2009-04-22 Ketokonazolenantiomer i mennesker

Country Status (12)

Country Link
US (4) US9198906B2 (enExample)
EP (1) EP2076265A4 (enExample)
JP (1) JP2010505866A (enExample)
AU (1) AU2007303219A1 (enExample)
BR (1) BRPI0719835A2 (enExample)
CA (1) CA2664800A1 (enExample)
IL (1) IL197986A0 (enExample)
NO (1) NO20091593L (enExample)
NZ (1) NZ576569A (enExample)
RU (1) RU2009116632A (enExample)
WO (1) WO2008042898A2 (enExample)
ZA (1) ZA200902127B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200706020B (en) * 2005-01-10 2008-12-31 Cortendo Invest Ab Publ Methods and compositions for treating diabetes, metabolic syndrome and other conditions
WO2007081980A2 (en) * 2006-01-10 2007-07-19 Diobex, Inc. Methods and compositions for treating prostate cancer
CA2664800A1 (en) 2006-10-02 2008-04-10 Timothy Andrew Stewart Ketoconazole enantiomer in humans
EP3049084A4 (en) * 2013-09-25 2017-03-15 Cortendo AB (publ) Novel functionalized 5-(phenoxymethyl)-1,3-dioxane analogs exhibitng cytochrome p450 inhibition
WO2016048984A1 (en) * 2014-09-25 2016-03-31 Cortendo Ab (Publ) Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole
WO2020180784A1 (en) * 2019-03-04 2020-09-10 Strongbridge Dublin Limited Methods of treating disease with levoketoconazole

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144346A (en) 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
US4503055A (en) 1979-03-26 1985-03-05 Janssen Pharmaceutica, N.V. Derivatives of [4-(piperazin-1-yl-phenyloxymethyl)-1,3-dioxolan-2-ylmethyl]-1H-imidazoles and 1H-1,2,4-triazoles
US4814333A (en) 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
US5432176A (en) 1988-11-29 1995-07-11 The John Hopkins University Method of retarding the progression of chronic renal failure
WO1994014447A1 (en) * 1992-12-22 1994-07-07 Sepracor, Inc. Methods and compositions of (-) ketoconazole for treating fungal yeast and dermatophyte infections
AU5851594A (en) 1992-12-22 1994-07-19 Georgetown University Methods and compositions of (+) ketoconazole for treating fungal, yeast and dermatophyte infections
IL109728A0 (en) 1993-05-28 1994-08-26 Pfizer Res & Dev Indoles
US5869255A (en) 1994-02-01 1999-02-09 The Regents Of The University Of California Probes labeled with energy transfer couples dyes exemplified with DNA fragment analysis
PT779810E (pt) 1994-08-09 2003-11-28 Cortendo Ab Utilizacao de cetoconazole e substancias relacionadas em medicamentos para o tratamento da diabetes tipo ii
US6642236B1 (en) 1998-12-14 2003-11-04 Cortendo Ab Methods for prophylactic treatment of cardiovascular disease with inhibitor of cortisol synthesis
US5584790A (en) 1995-09-08 1996-12-17 Beckman Instruments, Inc. Variable inclination centrifugation assembly for rapid separation of blood
CA2240115A1 (en) 1995-12-14 1997-06-19 Wallace T. Ashton Antagonists of gonadotropin releasing hormone
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5994334A (en) 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
SE9700642D0 (sv) 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet
BR9810378A (pt) 1997-07-01 2000-08-29 Novo Nordisk As Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
JP2002534512A (ja) 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドｇｌｐ−１アゴニスト
DE60012721T4 (de) 1999-03-29 2010-09-09 Uutech Ltd., Coleraine Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes
JP2002541146A (ja) 1999-04-02 2002-12-03 ニューロゲン コーポレイション アリールおよびヘテロアリール融合のアミノアルキル−イミダゾール誘導体および糖尿病薬としてのその使用
BR0010651A (pt) 1999-05-17 2002-03-19 Novo Nordisk As Composto, uso de um composto, composição farmacêutica, e, método para o tratamento e/ou prevenção de distúrbios ou de doenças mediadas por uma ação antagonìstica de glucagon
GB9915625D0 (en) 1999-07-02 1999-09-01 Cortendo Ab Method
AU7726600A (en) 1999-09-28 2001-04-30 Bayer Corporation Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use
GB0001449D0 (en) 2000-01-21 2000-03-08 Cortendo Ab Compositions
US20020055512A1 (en) 2000-01-21 2002-05-09 Cortendo Ab. Compositions for delivery of a cortisol antagonist
AU2001268661A1 (en) 2000-06-27 2002-01-08 Aventis Pharma S.A. 20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase
GB0118300D0 (en) 2001-07-26 2001-09-19 Cortendo Ab Formulations
US20040265827A1 (en) 2001-09-21 2004-12-30 Zhimin Zhu Regulation of human steroid 5-alpha reductase
CA2459926A1 (en) 2001-09-24 2003-04-03 Merck & Co., Inc. Screening and selection methods for statin drug combinations
WO2003027094A2 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
AU2003205926A1 (en) 2002-02-07 2003-09-02 Pfizer Limited Use of pde5 inhibitors such as sildenafil in the treatment of polycystic ovary syndrome
AU2003256988A1 (en) 2002-12-11 2004-06-30 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
US20040180868A1 (en) * 2003-03-12 2004-09-16 Mullally John P. Composition and method for treating inflammations by reducing C-reactive protein
WO2005113516A1 (en) 2004-05-14 2005-12-01 Neurocrine Biosciences, Inc. Uracil-type gonadotropin-releasing hormone receptor antagonists and methods related thereto
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
ZA200706020B (en) 2005-01-10 2008-12-31 Cortendo Invest Ab Publ Methods and compositions for treating diabetes, metabolic syndrome and other conditions
US20070116839A1 (en) * 2005-11-23 2007-05-24 The Coca-Cola Company High-Potency Sweetener Composition With C-Reactive Protein Reducing Substance and Compositions Sweetened Therewith
WO2007081980A2 (en) 2006-01-10 2007-07-19 Diobex, Inc. Methods and compositions for treating prostate cancer
CA2664800A1 (en) 2006-10-02 2008-04-10 Timothy Andrew Stewart Ketoconazole enantiomer in humans
US9394290B2 (en) 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases

Also Published As

Publication number Publication date
RU2009116632A (ru) 2010-11-10
NZ576569A (en) 2012-05-25
AU2007303219A1 (en) 2008-04-10
US20160067243A1 (en) 2016-03-10
EP2076265A4 (en) 2010-09-22
WO2008042898A2 (en) 2008-04-10
WO2008042898A9 (en) 2008-09-04
US20100093755A1 (en) 2010-04-15
BRPI0719835A2 (pt) 2014-05-06
IL197986A0 (en) 2009-12-24
EP2076265A2 (en) 2009-07-08
US20190209555A1 (en) 2019-07-11
CA2664800A1 (en) 2008-04-10
WO2008042898A3 (en) 2008-10-23
US20180125841A1 (en) 2018-05-10
US9198906B2 (en) 2015-12-01
ZA200902127B (en) 2010-07-28
JP2010505866A (ja) 2010-02-25

Similar Documents

Publication Publication Date Title
EP2217596B8 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
NO20080010L (no) GPCR-agonister
TNSN08534A1 (en) Modulators of metabolism and the treatment of disorders related thereto
NO20090064L (no) Pyrasoler som glucokinase aktivatorer
NO20081810L (no) Modulatorer av metabolisme og behandling av lidelser relatert dertil
EA201101189A1 (ru) Ингибитор sglt-2, предназначенный для лечения сахарного диабета типа 1, сахарного диабета типа 2, нарушенной толерантности к глюкозе или гипергликемии
CO6361917A2 (es) Tratamiento de la diabetes en pacientes con control glucemico insuficiente a pesar de la terapia con un farmaco oral o no oral antidiabetico
WO2006023703A3 (en) Method for treating sleep related breathing disorders
NO20084307L (no) Heterocykliske GPCR agonister
CL2008003201A1 (es) Composicion farmaceutica que comprende 0,5 a 50 mg de gaboxadol o una sal farmaceuticamente aceptable de este, y uno o mas inhibidores de pat1 y/o uno o mas inhibidores de oat, en donde dicha composicion brinda un perfil plasmatico in vivo con un tmax superior a 20 minutos, util en tratamientos de trastornos del sueno.
EA200801897A1 (ru) Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений
WO2010029089A3 (en) Combination therapy for the treatment of diabetes and related conditions
WO2007145834A3 (en) Benzamide derivatives and uses related thereto
EA201200793A1 (ru) Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
MA32272B1 (fr) Inhibiteurs de raf de pyrazole [3,4-b]pyridine
WO2007100535A3 (en) Oxyntomodulin derivatives
MX2009010894A (es) Derivados de 3-hidroquinazolin-4-ona para utilizarse como inhibidores de estearoil-coa-desaturasa.
NO20082159L (no) Triazolopyridinderivater som inhibitorer av lipaser og fosfolipaser
BRPI0917004A2 (pt) composto, composição farmacêutica, uso de um composto, e, métodos para melhorar a qualidade do sono, para tratar insônia, e para tratar ou controlar obesidade em um paciente mamífero em necessidade deste
MX2009003658A (es) Compuestos heterociclicos que contienen nitrogeno biciclico para utilizarse como inhibidores de desaturasa de estearoilo-coa.
MY147649A (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
WO2007145835A3 (en) Benzamide derivatives as modulators of 11beta-hsd1 for treating diabetes and obesity
PH12012502202A1 (en) Susbtituted heterocyclyl benzyl pyrazoles and use thereof
UA105487C2 (uk) Заміщені дигідропіразолони як інгібітори hif-проліл-4-гідроксилази

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application